Monitoring considerations include: Regular assessment of gastrointestinal tolerability and hydration status Evaluation of any changes in MS symptoms, with low threshold for neurological consultation Glucose monitoring in diabetic patients, with adjustment of other antihyperglycemic agents as needed Periodic assessment of weight loss progress and nutritional adequacy Monitoring for signs of pancreatitis (severe abdominal pain) or gallbladder disease For Wegovy patients, monitoring for depression or suicidal thoughts Patient counseling should address realistic expectations regarding weight loss (typically 15% of body weight over 68 weeks with the 2.4 mg dose plus lifestyle intervention, with less at earlier timepoints), the chronic nature of therapy, and the importance of lifestyle modifications
Clinically studied in ten trials and counting
NMN supplementation effectively countered the decrease in ovarian NAD + concentration in aged mice (Figure 1C)
It provides the structural integrity for your skin, hair, nails, bones, ligaments, and tendons
Finally, individuals with a history of heart failure, ischaemic heart disease, unstable angina, myocardial infarction, aortic aneurysm or dissection, stroke (ischaemic or haemorrhagic stroke), cerebral infarction, transient ischaemic attack, carotid intervention or surgery, coronary stenting, percutaneous coronary intervention (PCI) or coronary artery bypass before inclusion to the cohort or prior to the index event were also excluded
